2919583-43-8
Chemical Structure
Imneskibart
Synonym(s): AU-007; BD-8; BDG8
- CAS No.: 2919583-43-8
- Formula:N/A
- Molecular Weight:(146.504 kDa)
SMILES: [Imneskibart]
Biological Activity: Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imneskibart | 99.40% | Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mckean M, et al. Imneskibart, a human monoclonal antibody (mAb) that binds IL-2 and prevents CD25 binding,+ low-dose subcutaneous IL-2: phase 2 update on CPI-refractory melanoma and non-small cell lung cancer (NSCLC)[J]. Journal for Immunotherapy of Cancer, 2025, 13(Suppl 2): A739-A739.
- [2]. Rasco D W, et al. Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors[J]. 2024.
